"A
perfect storm" of complex macro and micro factors have forced the life
sciences industry to re-examine traditional business models and location
strategies, and "rebalance their portfolio of assets among regions of the
world," according to a new Jones Lang LaSalle (JLL) study.
Struggling economies, increased competition,
pricing pressure, depleted new-product pipelines and heightened regulatory
processes "have all strained profitability, influencing the industry’s
facility and location decisions," reveal the Global Life Sciences Cluster
Report.
Major life sciences companies continue to
center their headquarter relocations and biotech start-up/innovation activity
in clusters within Europe, the U.S. and Japan, notes the report. However,
"the emerging markets of Brazil, India, China and others throughout Asia
and Latin America are becoming more competitive. Increasingly they are trying
to balance their operations among the Americas, EMEA (Europe, the Middle East
and Africa), and Asia Pacific."
The research shows that emerging market
governments in Asia and Latin America are making significant capital
investments. They also are improving political policies to become more
competitive in high-tech aspects of the industry and be in contention for CRO
opportunities. For example, "massive" research parks in these emerging
global clusters are fuelling growth in R&D. Related highlights from the
study reveal that:
Biopolis, Singapore’s largest research park,
spans 2.4 million sq. ft. and has dedicated space for biomedical R&D and
promoting collaboration between private/public scientific communities.
"Among the emerging clusters, Singapore is best poised to increase its
high-tech research presence based on its strong intellectual property laws,
stable and industry-supportive political structures, and mature business
environment that make the island-nation an ideal launching pad into other
Asia-Pacific markets."
Suzhou BioBay in China encompasses over nine
square miles and offers innovation incubator and accelerator support. "In
China, the government’s five-year plan includes programs designed to stimulate
growth in sectors such as biotechnology. These investments are paying off with
several big pharmaceutical players expanding beyond manufacturing facilities by
opening research operations in the country, the intellectual property risks
being outweighed by the sheer size of the market."
Butantan Institute in Brazil, a research
development and training center, is the largest producer of immunobiologics and
biopharmaceuticals in Latin America.
In India, the study says companies already
have made "significant headway in manufacturing generic versions of
expensive drugs, showing they have the local skills to be globally competitive.
The government hopes to expand beyond the country’s strong generic and contract
manufacturing presence into biosimilars and contract research."
In Latin America, several countries are
emerging as competitive clusters in agricultural biotechnology.
"Infrastructure built around this sector could serve as a springboard into
further developments in human-use drugs and biotechnology."
Although emerging clusters are playing a more
prominent role in the global life sciences industry, the study states that
"Europe, the United States and Japan are undoubtedly still world leaders
in the sector, especially in the R&D aspects of the value chain."
Area Development Online News Desk
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.
No comments:
Post a Comment